ESC Congress 2022 (Photo by Kyle LaHucik)

#ESC22: Cin­Cor CMO’s 17-year jour­ney in bring­ing a new hy­per­ten­sion drug to mar­ket con­tin­ues

BARCELONA — Six­teen years ago, Ma­son Free­man was “very dis­ap­point­ed.” A first-in-hu­man study of an al­dos­terone syn­thase in­hibitor, or ASI, had done what it was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.